Back to top

Image: Bigstock

Lilly vs. Pfizer: Which Drugmaker Has Stronger Growth Prospects?

Read MoreHide Full Article

Key Takeaways

  • Lilly's Mounjaro and Zepbound generated $43.8 billion in combined sales in the first nine months of 2026.
  • Pfizer is expanding its oncology and obesity pipelines to offset declining COVID sales and patent expirations.
  • Lilly's GLP-1 franchise, new product launches and expanding pipeline support its strong growth outlook.

Eli Lilly & Company (LLY - Free Report) and Pfizer (PFE - Free Report) are two leading U.S. pharmaceutical giants with diversified portfolios and robust research and development capabilities. Lilly has established a dominant position in the cardiometabolic market, driven by soaring demand for its blockbuster GLP-1 drugs, Mounjaro and Zepbound. Meanwhile, Pfizer's oncology business remains a key pillar of its growth strategy.

Beyond cardiometabolic treatments, Lilly has a presence in oncology, immunology and neuroscience, among other therapeutic areas. Pfizer's portfolio extends across vaccines, inflammation and immunology, and rare diseases.

Both drugmakers are backed by promising pipelines and continue to invest in innovative therapies to fuel future growth. However, with each company facing distinct opportunities and challenges, which stock offers greater upside potential for investors? Let's examine their underlying fundamentals, growth prospects and potential headwinds to determine which is the better investment choice.

The Case for Lilly Stock

Lilly has seen extraordinary momentum in its cardiometabolic franchise. Its blockbuster drugs, Mounjaro for type II diabetes and Zepbound for obesity, have become some of the fastest-growing medicines in pharmaceutical history, driven by enormous global demand for Mounjaro and Zepbound. These therapies account for around 65% of the company’s total revenues and have become key top-line drivers for Lilly.

In the first nine months of 2026, Mounjaro and Zepbound generated combined sales of $43.8 billion. Growing patient demand, broader insurance coverage and international expansion are driving growth.

Lilly’s newly launched once-daily oral GLP-1 pill, Foundayo (orforglipron), for treating obesity could be a commercial game-changer for Lilly. Oral pills will be a more convenient alternative to the currently available once-weekly injectable obesity treatments like Zepbound and rival Novo Nordisk’s (NVO - Free Report) Wegovy. The launch uptake for Foundayo has been encouraging, with the drug recording $281 million in sales already in 2026 so far, supported by physician education, broad commercial access and continued international launches.

To maintain leadership in the GLP-1 market, Lilly is developing several next-generation, more powerful and more convenient GLP-1–based treatments, including oral options and multi-acting candidates. Retatrutide is one of Lilly’s most important late-stage pipeline candidates, targeting GLP-1, GIP and glucagon pathways and potentially delivering greater weight loss and broader metabolic benefits than current therapies. With late-stage studies spanning obesity, type II diabetes, obstructive sleep apnea (OSA) and other indications, Lilly plans to seek FDA approval in the first quarter of 2027, potentially creating another multibillion-dollar growth driver.

Lilly’s growth story is increasingly diversifying beyond its GLP-1 franchise, with newer therapies such as Omvoh, Jaypirca, Ebglyss, Kisunla and Inluriyo gaining traction across multiple therapeutic areas. These products are becoming meaningful growth contributors.

Lilly has also pursued an aggressive acquisition strategy to strengthen its pipeline and diversify its long-term growth opportunities. In 2026, the company has acquired several biotech firms, including Orna Therapeutics, Kelonia Therapeutics, Centessa Pharmaceuticals and AtaiBeckley, expanding its presence across cell therapy, neuroscience and other emerging treatment areas. These deals should help reduce its long-term reliance on GLP-1 drugs.

Lilly has its share of problems. Pricing pressure is becoming increasingly visible. Worldwide realized prices fell 15% during the third quarter, including a 7% decline in the United States and a 29% decline internationally.  Price is expected to continue to be a drag on top-line growth in 2027 as well. Rising competition in the GLP-1 diabetes/obesity market is a key headwind. Also, sales of late life-cycle products like Trulicity and Taltz have declined this year.

The Case for PFE Stock

Pfizer's business mix has changed significantly over the past few years. During the pandemic, the company became heavily dependent on COVID-19 products, Comirnaty (COVID-19 vaccine) and Paxlovid (oral antiviral). However, the company is gradually diversifying its portfolio through a combination of internal product launches and strategic acquisitions like Seagen, Metsera and Biohaven.

Pfizer’s newly launched and acquired products delivered $3.8 billion in revenues in the third quarter and grew 32% operationally, reflecting strong contributions from products such as Padcev, Nurtec and Lorbrena. Pfizer is investing behind these products to mitigate its loss of exclusivity (LOE) headwinds over the next several years. Its launched and acquired products rose 22% operationally in the first quarter and 18% in the second quarter.

Pfizer is one of the world’s leading oncology drugmakers with a broad portfolio of marketed cancer therapies as well as a deep oncology pipeline. Oncology sales comprise around 27% of its total revenues. Its oncology revenues grew 6% in the first nine months of 2026, driven by drugs like Lorbrena, the Braftovi-Mektovi combination and Padcev.

The company is also rebuilding its pipeline in oncology and obesity, which it believes can drive growth in 2028 and beyond. Pfizer plans to advance 20-plus studies for obesity and related comorbidities in 2026, including 10 ongoing and planned phase III studiesfor berobenatide (PF’3944), an investigational GLP-1 receptor agonist acquired through its November 2025 acquisition of Metsera. Berobenatide is being developed for weekly and monthly dosing for chronic weight management and obesity-related conditions, including knee osteoarthritis and obstructive sleep apnea. Pfizer is targeting the first of a series of potential approvals for berobenatide in 2028. However, in the obesity space, Pfizer lags far behind leaders like Lilly and Novo Nordisk.

A key candidate in its oncology pipeline is tivunatamig/PF-08634404, a dual PD-1/VEGF inhibitor in-licensed from Chinese biotech 3SBio in 2025. Pfizer has initiated several studies, including two pivotal phase III studies for tivunatamig in first-line metastatic colorectal cancer and first-line NSCLC. Two additional phase III studies are expected to begin before year-end. Pfizer aims to establish PF-08634404 as a potential backbone therapy across multiple tumor types.

Pfizer’s significant cost reduction and efforts to improve R&D productivity measures are also driving profit growth. Pfizer offers one of the highest dividend yields in the sector.

However, Pfizer faces a significant patent cliff later this decade. It expects a significant negative impact on revenues from the LOE cliff in the 2026-2030 period as several of its key products, including Eliquis, Ibrance, Xeljanz and Xtandi, face patent expirations. The LOE cliff is expected to hurt sales by approximately $1.1 billion in 2026. Sales of its COVID products will also continue to decline.

However, Pfizer expects its recently launched and acquired products, along with a strong pipeline, to help it return to growth from 2029 onward. Although Pfizer’s 2026 sales guidance indicates minimal growth, the company expects a risk-adjusted high single-digit revenue CAGR for five years, starting from year-end 2028.

How Do Estimates Compare for LLY & PFE?

The Zacks Consensus Estimate for LLY’s 2026 sales and EPS implies a year-over-year increase of 40.9% and 46.1%, respectively. EPS estimates for 2026 have risen from $33.86 to $35.36 over the past 30 days.

LLY Estimate Movement

Zacks Investment ResearchImage Source: Zacks Investment Research

The Zacks Consensus Estimate for Pfizer’s 2026 sales and EPS implies a year-over-year increase of 0.8% and a decline of 6.5%, respectively. Earnings estimates for 2026 have risen from $2.95 per share to $3.01 per share over the past 60 days.

PFE Estimate Movement

Zacks Investment ResearchImage Source: Zacks Investment Research

Price Performance and Valuation of LLY & PFE

So far this year, Lilly’s stock has risen 25.4%, while Pfizer’s stock is up 10.4%. The industry has risen 21.2% in the said time frame.

Zacks Investment ResearchImage Source: Zacks Investment Research

Pfizer looks more attractive than LLY from a valuation standpoint. Going by the price/earnings ratio, LLY’s shares currently trade at 27.58 forward earnings, much higher than 19.01 for the industry. However, LLY’s stock is trading below its 5-year mean of 34.56. Pfizer’s shares currently trade at 9.27 forward earnings, significantly lower than the industry and the stock’s 5-year mean of 9.25.

Zacks Investment ResearchImage Source: Zacks Investment Research

Lilly’s dividend yield is 0.5%, while Pfizer's is around 6.3%.

PFE or LLY: Which is a Better Pick?

Lilly and Pfizer both have a Zacks Rank #3 (Hold), which makes choosing one stock a difficult task. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

After taking a hit over the past three years largely due to a sharp decline in sales of its COVID-related products, Pfizer’s stock is gradually recovering. However, the market is still concerned about Pfizer’s ability to replace declining COVID-related revenues and offset upcoming patent expirations through new product launches, pipeline development and contributions from acquisitions. A persistent gap between management’s growth expectations and more conservative consensus forecasts underscores that caution.

On the other hand, Lilly remains one of the most compelling growth stories in the pharmaceutical industry, supported by its significant price appreciation in the past few years, dominant position in the rapidly expanding obesity and diabetes markets, a diversified late-stage pipeline and strong financial performance, which make it a clear winner over Pfizer.

Published in